REAL EVIDENCE. BETTER OUTCOMES.

Weight loss is a number.
Body composition is the outcome.

Follow the evidence behind GLP-1s, peptides, amylin drugs and muscle-preservation therapies — from scale weight to fat mass, lean mass, function and regulatory status.

Get the free 2026 Evidence Map Explore the Therapy Atlas — $29

Evidence-based Source-labeled Pipeline-aware Outcome-focused

Evidence intelligence for the therapies shaping body composition.

M0–M5 evidence maturity Body composition beyond scale weight Pipeline watch as evidence changes

RecompSignal Therapy Atlas October 2026 edition cover

NOW AVAILABLE · THERAPY ATLAS 2026

One reference for the evidence,
the reports and the unknowns.

Explore peptide and therapy research with clinical findings, community experiences and molecular identity kept in clear context.

355 pages131 catalog records23 molecular detail plates

Study history, reported benefits and contrary experiences
Separate evidence ratings, source trails and explicit research gaps
Bond diagrams, searchable text and clickable indexes

$29 one-time · Atlas PDF + two-page reader guide

Explore the Atlas Read the free sample

Catalog records include forms, blends and adjuncts; coverage varies. Educational reference, not personal treatment guidance.

Why RecompSignal

Not every health claim deserves the same confidence.

We separate regulatory status, evidence maturity and outcome-specific evidence. A therapy can have excellent weight-loss data but much weaker evidence for preserving lean mass. FDA approval for one indication does not establish effectiveness for another.

Established benchmark

Tirzepatide

M5 Approved

Deep weight and body-composition evidence.

Established benchmark

Semaglutide

M5 Approved

Extensive obesity evidence with direct composition data.

Pipeline flagship

Retatrutide

M4 Investigational

Exceptional weight signal; composition evidence still maturing.

Muscle preservation

Bimagrumab

M3 Investigational

Composition-first profile with lean-mass gain signal.

Evidence

Human maturity, source quality, and claim-specific confidence.

Composition

Weight, fat mass, visceral fat, lean mass, skeletal muscle and function.

Pipeline

Trial completions, regulatory milestones and new body-composition readouts.

Hype vs Evidence

Popular claims separated from what has actually been demonstrated in humans.

Study details behind the signal

Every Signal Card now includes doses studied, study context and source links. Explore newer coverage of apitegromab, eloralintide and approved orforglipron.

Understand the evidence scores · See what changed

How to use RecompSignal

From headline to evidence — in three steps.

Start with the signal, compare the outcome that matters, then follow what changes as new human evidence arrives.

Explore

Open a Signal Card to see evidence maturity, regulatory status and the outcomes actually studied.

Browse Signal Cards → 02

Compare

Look beyond headline weight loss to fat mass, lean mass, function and strength of evidence.

Compare evidence → 03

Track

Follow late-stage programs, trial readouts and emerging body-composition evidence as the field moves.

Open Pipeline Watch →

Methodology

Evidence maturity shows how far the evidence has developed.

The RecompSignal M0–M5 framework prevents preliminary biology from being presented like mature clinical evidence. Outcome Evidence Strength is shown separately for weight, fat/composition, lean mass and function.

Established: multiple strong human trials plus substantial clinical or regulatory experience.

Advanced clinical: large controlled human evidence, usually late-stage development.

Clinical: meaningful controlled human efficacy evidence.

Preliminary human: small, pilot, uncontrolled, or pharmacology-focused human studies.

Preclinical: animal, cell, or mechanistic evidence dominates.

Unsupported: adequate evidence for the claim evaluated has not been demonstrated.

Read the full methodology

The Muscle Preservation Race

The next competition may be about what the lost pounds are made of.

A growing class of therapies is testing whether pharmacologic weight loss can become more fat-selective while preserving lean tissue, strength and function.

Explore Muscle Preservation

Bimagrumab Activin pathway · composition-first signal Trevogrumab Myostatin pathway · GLP-1 combination research Taldefgrobep Pipeline watch · direct fat/lean endpoints

Compare the Evidence

“Which loses more weight?” is only one column.

Therapy	Human maturity	Weight	Fat/composition	Lean mass	Status
Tirzepatide	M5	5/5	3/5	3/5	Approved
Semaglutide	M5	5/5	2/5	2/5	Approved
Retatrutide	M4	3/5	3/5	3/5	Investigational
Bimagrumab	M3	3/5	4/5	4/5	Investigational
BPC-157	M2	0/5	0/5	0/5	Experimental
Orforglipron	M5	5/5	0/5	0/5	Approved

Scores apply to the cited outcome evidence, not treatment quality. 0 means not established in the reviewed sources. A lean-mass score can describe lean loss. Scoring rubric.

Open full comparison hub Semaglutide vs Tirzepatide

Pipeline Watch

Static guides age. The pipeline keeps moving.

RecompSignal tracks clinical trial completions, regulatory events and new body-composition readouts — the recurring layer behind the future RecompSignal Pro research service.

2026 watch

Taldefgrobep

Phase 2 obesity program with direct fat- and lean-mass endpoints.

Regulatory watch

Retatrutide

Late-stage program moving toward a potential U.S. regulatory submission.

Human evidence transition

MOTS-c

Randomized Phase 2a metabolic study now brings the peptide into meaningful human testing.

Open full pipeline watch

Current · Popular · Emerging

Understand the therapies shaping body composition now.

A 68-page evidence research package covering current, popular and emerging weight-loss and body-composition therapies—built to help you interpret what was studied, what was measured and what remains uncertain.

Studied-dose research index — protocols, not recommendations 13 in-depth standardized therapy profiles Comparison quick reference Printable research worksheets

Introductory price$19One-time purchase

Explore the Evidence Companion Ready to buy? Secure checkout — $19

Read the full package description, preview the contents and review the terms before checkout. Includes one complimentary revised edition released within six months.

Educational use only — not medical advice. Studied doses describe research protocols and are not dosing recommendations.

RecompSignal Evidence Companion 2026 product preview

First edition

RecompSignal Studied-Dose Research Index 2026 cover

FOCUSED RESEARCH TOOL

Only need the studied-dose index?

Get the three-page reference covering 13 current, popular and emerging therapies for $10. Every research regimen stays attached to population, formulation, duration and evidence status.

Get the standalone index — $10The complete $19 Companion remains the best value for profiles, interpretation and comparison tools.

SUBMISSION RECEIVED